202 related articles for article (PubMed ID: 16165408)
1. Independent pathways in the modulation of osteoclastic resorption by intermediates of the mevalonate biosynthetic pathway: the role of the retinoic acid receptor.
van Beek E; Löwik C; Karperien M; Papapoulos S
Bone; 2006 Feb; 38(2):167-71. PubMed ID: 16165408
[TBL] [Abstract][Full Text] [Related]
2. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.
van beek E; Löwik C; van der Pluijm G; Papapoulos S
J Bone Miner Res; 1999 May; 14(5):722-9. PubMed ID: 10320520
[TBL] [Abstract][Full Text] [Related]
3. Mevalonates restore zoledronic acid-induced osteoclastogenesis inhibition.
Nagaoka Y; Kajiya H; Ozeki S; Ikebe T; Okabe K
J Dent Res; 2015 Apr; 94(4):594-601. PubMed ID: 25535203
[TBL] [Abstract][Full Text] [Related]
4. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
Luckman SP; Hughes DE; Coxon FP; Graham R; Russell G; Rogers MJ
J Bone Miner Res; 1998 Apr; 13(4):581-9. PubMed ID: 9556058
[TBL] [Abstract][Full Text] [Related]
5. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates.
van Beek ER; Cohen LH; Leroy IM; Ebetino FH; Löwik CW; Papapoulos SE
Bone; 2003 Nov; 33(5):805-11. PubMed ID: 14623056
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors.
Van Beek ER; Löwik CW; Papapoulos SE
Bone; 2002 Jan; 30(1):64-70. PubMed ID: 11792566
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
[TBL] [Abstract][Full Text] [Related]
8. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.
Fisher JE; Rogers MJ; Halasy JM; Luckman SP; Hughes DE; Masarachia PJ; Wesolowski G; Russell RG; Rodan GA; Reszka AA
Proc Natl Acad Sci U S A; 1999 Jan; 96(1):133-8. PubMed ID: 9874784
[TBL] [Abstract][Full Text] [Related]
9. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
[TBL] [Abstract][Full Text] [Related]
10. Compactin suppresses bone resorption by inhibiting the fusion of prefusion osteoclasts and disrupting the actin ring in osteoclasts.
Woo JT; Kasai S; Stern PH; Nagai K
J Bone Miner Res; 2000 Apr; 15(4):650-62. PubMed ID: 10780857
[TBL] [Abstract][Full Text] [Related]
11. Identifying Potential Therapeutics for Osteoporosis by Exploiting the Relationship between Mevalonate Pathway and Bone Metabolism.
Hasan WNW; Chin KY; Jolly JJ; Ghafar NA; Soelaiman IN
Endocr Metab Immune Disord Drug Targets; 2018; 18(5):450-457. PubMed ID: 29683099
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates: from the laboratory to the clinic and back again.
Russell RG; Rogers MJ
Bone; 1999 Jul; 25(1):97-106. PubMed ID: 10423031
[TBL] [Abstract][Full Text] [Related]
13. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.
Nishida S; Tsubaki M; Hoshino M; Namimatsu A; Uji H; Yoshioka S; Tanimori Y; Yanae M; Iwaki M; Irimajiri K
Biochem Biophys Res Commun; 2005 Mar; 328(1):91-7. PubMed ID: 15670755
[TBL] [Abstract][Full Text] [Related]
14. The Role of Geranylgeraniol in Managing Bisphosphonate-Related Osteonecrosis of the Jaw.
Chin KY; Ekeuku SO; Trias A
Front Pharmacol; 2022; 13():878556. PubMed ID: 35600875
[TBL] [Abstract][Full Text] [Related]
15. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates.
van Beek E; Pieterman E; Cohen L; Löwik C; Papapoulos S
Biochem Biophys Res Commun; 1999 Oct; 264(1):108-11. PubMed ID: 10527849
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid and geranylgeraniol regulate cellular behaviour and angiogenic gene expression in human gingival fibroblasts.
Zafar S; Coates DE; Cullinan MP; Drummond BK; Milne T; Seymour GJ
J Oral Pathol Med; 2014 Oct; 43(9):711-21. PubMed ID: 24762323
[TBL] [Abstract][Full Text] [Related]
17. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates.
Rogers MJ
Calcif Tissue Int; 2004 Dec; 75(6):451-61. PubMed ID: 15332174
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of action of bisphosphonates: current status.
Roelofs AJ; Thompson K; Gordon S; Rogers MJ
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6222s-6230s. PubMed ID: 17062705
[TBL] [Abstract][Full Text] [Related]
19. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
Bergstrom JD; Bostedor RG; Masarachia PJ; Reszka AA; Rodan G
Arch Biochem Biophys; 2000 Jan; 373(1):231-41. PubMed ID: 10620343
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton.
Rogers MJ; Mönkkönen J; Munoz MA
Bone; 2020 Oct; 139():115493. PubMed ID: 32569873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
